This is a Phase II study of cetuximab, carboplatin and radiotherapy (RT) in patients with
Locally Advanced Head and Neck Carcinomas (LAHNC) who are unfit for cisplatin.
The aim of this study is to show the feasibility and safety profile of the combination of
cetuximab, carboplatin and RT in treatment of patients with LAHNC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Trans Tasman Radiation Oncology Group Trans-Tasman Radiation Oncology Group (TROG)